An approach to the radiosensitization of human tumors

Cancer Journal from Scientific American

Volumn 2, Issue 4, 1996, Pages 184-193

  Kinsella, Timothy J ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; RADIOSENSITIZING AGENT;

ANIMAL; ARTICLE; CELL CYCLE; HUMAN; NEOPLASM;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL CYCLE; HUMANS; NEOPLASMS; RADIATION-SENSITIZING AGENTS;

EID: 0001002341     PISSN: 10814442     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (85)

1. Ritter MA. New approaches to cell kinetics in human tumors. Curr Prob Cancer 1993, 27:325-368.
2. Suit HD. Local control and patient survival. Int J Radiat Oncol Biol Phys 1992; 23:653-660.
3. Fowler JF. Rapid repopulation in radiotherapy: a debate on mechanism. The phantom of tumor treatment-continually rapid proliferation unmasked. Radiother Oncol 1991; 22:156-158.
4. Begg AC, McNally NJ, Shrieve DC et al. A method to measure the duration of DNA synthesis and the potential doubling time from a single sample. Cytometry 1985; 6:620-626.
5. Ritter MA, Fowler JF, Kim Y et al. Single biopsy, tumor kinetic analyses: a comparison of methods and an extension to shorter sampling intervals. Int J Radiat Oncol Biol Phys 1992; 23:811-820.
6. Harari PM, Kinsella TJ. Advances in radiation therapy for head and neck cancer. Curr Opinion Oncol 1995; 7:248-254.
7. Maity A, McKenna WG, Muschel RJ. The molecular basis for cell cycle delays following ionizing radiation. Radiat Oncol 1994; 31:143.
8. Gudas J, Knight GB, Pardee AB. Nuclear posttranslational processing of thymidine kinase mRNA at the onset of DNA synthesis. Proc Natl Acad Sci USA 1988; 85:4705-4709.
9. Mikulits W, Hengstschlager M, Sauer T et al. Overexpression of thymidine kinase mRNA eliminates cell cycle regulation of thymidine kinase enzyme activity. J Biol Chem 1996; 271:853-860.
10. Maehara Y, Nakamura H, Nakane Y et al. Activities of various enzymes of pyrimidine nucleotides and DNA synthesis in normal and neoplastic human tissues. Gann 1982; 73:289-298.
11. Boothman DA, Meyers M, Lee SW. Isolation of x-ray-inducible transcripts from radioresistant human melanoma cells. Proc Natl Acad Sci USA 1993; 90:7200-7204.
12. Boothman DA, Davis TW, Sahijdak WM. Enhanced expression of thymidine kinase in human cells following ionizing radiation. Int J Radiat Oncol Biol Phys 1994; 30:391-398.
13. Al-Nabulsi IY, Takamiya Y, Voloshin A et al. Expression of thymidine kinase is essential to low dose rate radiation resistance of rat glioma cells. Cancer Res 1994; 54:5614-5617.
14. Jenh C-H, Rao LG, Johnson EF. Regulation of thymidylate synthase enzyme synthesis in 5-fluorodeoxyuridine-resistant mouse fibroblasts during the transition from the resting to growing state. J Cell Physio 1985; 122:149-154.
15. Pestalozzi BC, McGinn CJ, Kinsella TJ et al. Increased thymidylate synthase protein levels are principally associated with proliferation but not cell cycle phase in asynchronous human cancer cells. Br J Cancer 1995; 71:1151-1157.
16. Ayusawa D, Shimizu K, Koyama H et al. Cell-cycle directed regulation of thymidylate synthase messenger RNA in human diploid fibroblasts stimulated to proliferate. J Mol Biol 1986; 190:556-567.
17. Chu E, Koeller DM, Casey JL et al. Autoregulation of human thymidylate synthase messenger RNA translation by thymidylate synthase. Proc Natl Acad Sci USA 1991; 88:8977-8981.
18. Chu E, Voeller D, Koeller DM et al. Identification of an RNA binding site for human thymidylate synthase. Proc Natl Acad Sci USA 1993; 90:517-521.
19. Chu E, Copur S, Jones KL et al. Thymidylate synthase regulates the translation of p53 mRNA. Proc Amer Assoc Cancer Res 1995; 36:563.
20. Chu E, Koeller DM, Johnston PG et al. Regulation of thymidylate synthase in human colon cancer cells treated with 5-fluorouracil and interferon-gamma. Mol Pharmacol 1993; 43:527-533.
21. Johnston PG, Fisher ER, Rockette HE et al. The role of thymidylate synthase expression in prognosis and outcome to adjuvant chemotherapy in patients with rectal cancer. J Clin Oncol 1994; 12:2640-2647.
22. Alexander HR, Grem JL, Hamilton JR et al. Thymidylate synthase protein expression: association with response to neoadjuvant chemotherapy and resection for locally advanced gastric and gastroesophageal adenocarcinoma. Cancer J Sci Am 1995; 1:49-54.
23. Miller EM, Kinsella TJ. Radiosensitization by fluorodeoxyuridine: effects on thymidylate synthase inhibition and cell synchronization. Cancer Res 1992; 52:1687-1694.
24. Elledge SJ, Zhou Z, Allen JB, Navas TA DNA damage and cell cycle regulation of ribonucleotide reductase. Bioessays 1993; 15:333-339.
25. Reichard P. From RNA to DNA, why so many ribonucleotide reductases? Science 1993; 260:1773-1777.
26. Kunugi KA, Sharma R, Sosnay P et al. Correlation of overexpression of ribonucleotide reductase and radioresistance in a human head and neck squamous cell cancer model. Proc Amer Assoc Cancer Res 1996; 37:609.
27. Sinclair WK. The combined effect of hydroxyurea and x-rays on Chinese hamster cells in vitro. Cancer Res 1968; 28:198-206.
28. Fram RJ, Kufe DW. Inhibition of DNA excision repair and the repair of x-ray-induced DNA damage by cytosine arabinoside and hydroxyurea. Pharmacol Ther 1985; 31:165-176.
29. Kuo M-L, Kunugi KA, Lindstrom MJ, Kinsella TJ. The interaction of hydroxyurea and iododeoxyuridine on the radiosensitivity of human bladder cancer cells. Cancer Res 1995; 55:2800-2805.
30. Kuo M-L, Kunugi KA, Lindstrom MJ, Kinsella TJ. The interaction of hydroxyurea and ionizing radiation in human cervical carcinoma cells: a mechanistic study. Cancer Res 1996; in press.
31. Sinclair WK. Hydroxyurea revisited: a decade of clinical effects studies. Int J Radiat Oncol Biol Phys 1981; 7:631-637.
32. Piver MS, Vongtama V, Emrich LJ. Hydroxyurea plus pelvic radiation versus placebo plus pelvic radiation in surgically staged stage IIIB cervical cancer. J Surg Oncol 1987; 35:129-144.
33. Piver MS, Khalil M, Emrich LJ. Hydroxyurea plus pelvic irradiation versus placebo plus pelvic irradiation in nonsurgically staged stage IIIB cervical cancer. J Surg Oncol 1989; 42:120-125.
34. Stehman FB, Bundy BN, Thomas G et al. Hydroxyurea versus misonidazole with radiation in cervical carcinoma: long term follow-up of a Gynecologic Oncology Group trial. J Clin Oncol 1993; 11:1523-1528.
35. McGinn CJ, Kinsella TJ. The clinical rationale for S-phase radiosensitization in human minors. Curr Prob Cancer 1993; 27:273-324.
36. Kinsella TJ, Dobson PA, Mitchell JB, Fornace AJ. Enhancement of X-ray induced DNA damage by pre-treatment with halogenated pyrimidine analogs. Int J Radiat Oncol Biol Phys 1987; 13: 733-739.
37. Iliakis G, Kurtzman S, Pantelias G, Okayasu R. Mechanism of radiosensitization by halogenated pyrimidines: effect of BrdU on radiation induction of DNA and chromosome damage and its correlation with cell killing. Radiat Res 1989; 119:286-304.
38. Fornace AJ, Dobson PP, Kinsella TJ. Enhancement of radiation damage in cellular DNA following unifilar substitution with iododeoxyuridine. Int J Radiat Oncol Biol Phys 1990; 18:873-878.
39. Lawrence TS, Davis MN, Maybaum J, Stetson PL, Ensminger WD. The effect of single versus double-strand substitution on halogenated pyrimidine-induced radiosensitization and DNA strand breakage in human tumor cells. Radiat Res 1990; 123:192-198.
40. Iliakis G, Kurtzman S. Mechanism of radiosensitization by halogenated pyrimidines: bromodeoxyuridine and alpha-arabinofuranosyladenine affect similar subsets of radiation-induced potentially lethal lesions in plateau-phase Chinese hamster ovary cells. Radiat Res 1991; 127-45-51.
41. Miller EM, Fowler JF, Kinsella TJ. Linear-quadratic analysis of radiosensitization by halogenated pyrimidines. I. Radiosensitization of human colon cancer cells by iododeoxyuridine. Radiat Res 1992; 131:81-89.
42. Schultz CJ, Gaffney DK, Lindstrom M, Kinsella TJ. Iododeoxyuridine radiosensitization of human glioblastoma cells exposed to acute and chronic gamma irradiation: mechanistic implications and clinical relevance. Cancer J Sci Am 1995; 1:151-161.
43. Lawrence TS, Davis MA, Normolle DP. Effect of bromodeoxyuridine on radiation-induced DNA damage and repair based on DNA fragment size using pulsed field gel electrophoresis. Radiat Res 1995; 144:282-287.
44. Fowler JF, Kinsella TJ. The limiting radiosensitization of tumors by S-phase sensitizers. Br J Cancer 1996; 73: in press.
45. Rodriguez R, Ritter MA, Fowler JF, Kinsella TJ. Kinetics of cell labeling and thymidine replacement after continuous infusion of halogenated pyrimidines in vivo. Int J Radiat Oncol Biol Phys 1994; 29:105-113.
46. Speth PA, Kinsella TJ, Chang AE et al. Selective incorporation of iododeoxyuridine in DNA of hepatic metastases versus normal human liver. Clin Pharmacol Ther 1988; 44:369-375.
47. Cook JA, Glass J, Lebovics R et al. Measurement of thymidine replacement in patients with high grade gliomas, head and neck tumors, and high grade sarcomas after continuous intravenous infusion of 5-iododeoxyuridine. Cancer Res 1992; 52:719-725.
48. Knol JA, Walker SC, Robertson JM et al. Incorporation of 5-bromo-2′-deoxyuridine into colorectal liver metastases and liver in patients receiving a 7-day hepatic arterial infusion. Cancer Res 1995; 55:3687-3691.
49. Kinsella TJ, Collins J, Rowland J et al. Pharmacology and phase I/II study of continuous intravenous infusions of iododeoxyuridine and hyperfractionated radiotherapy in patients with glioblastoma multiforme. J Clin Oncol 1988; 6871-6879.
50. Greenberg HS, Chandler WF, Diaz RF et al. Intra-arterial bromodeoxyuridine radiosensitization and radiation in treatment of malignant astrocytomas. J Neurosurg 1988; 69:500-505.
51. Phillips TL, Levin VA, Ahn DK et al. Evaluation of bromodeoxyuridine in glioblastoma multiforme: a Northern California Cancer Center phase II study. Int J Radiat Oncol Biol Phys 1991; 21: 709-714.
52. Sullivan FJ, Herscher LL, Cook JA et al. National Cancer Institute (Phase II) study of high-grade glioma treated with accelerated hyperfractionated radiation and iododeoxyuridine: encouraging results in anaplastic astrocytoma. Int J Radiat Oncol Biol Phys 1994; 30:583-590.
53. Levin VA, Prados MD, Wara WM et al. Radiation therapy and bromodeoxyuridine chemotherapy followed by procarbazine, lomustine and vincristine for the treatment of anaplastic gliomas. Int J Radiat Oncol Biol Phys 1995; 32:75-83.
54. Urtasun RC, Kinsella TJ, DelRowe J et al. Survival improvement in anaplastic astrocytoma combining external radiation with halogenated pyrimidines. Final report of RTOG 86-12, phase I-II study. Int J Radiat Oncol Biol Phys 1996; 35: in press.
55. Lawrence TS, Davis MA, Stetson PL et al. Kinetics of bromodeoxyuridine elimination from human colon cancer cells in vitro and in vivo. Cancer Res 1994; 54:2964-2968.
56. Robertson JR, Johnston C, Eisbruch A et al. A phase I/II study of bromodeoxyuridine (BrdU) and radiation therapy (RT) for locally advanced cervix cancer. Proc Am Soc Clin Oncol 1995; 14:201.
57. Miller EM, Kunugi KA, Kinsella TJ. Effects of 5′-aminothymidine and leucovorin on the radiosensitization by iododeoxyuridine in human colon cancer cells. Clin Cancer Res 1995; 1:407-416.
58. Kinsella TJ, Glennon MC, Kunugi KA, Lindstrom MJ. In vivo modulation of 5-iododeoxyuridine metabolism and incorporation into cellular DNA by 5′-amino-5′-deoxythymidine in normal mouse tissues and two human colon cancer xenografts. Clin Cancer Res 1996; 2 in press.
59. Kinsella TJ, Kunugi KA, Vielhuber K et al. In vivo comparison of oral 5-iodo-2′-deoxyuridine and 5-iodo-2-pyrimidinone-2′-deoxyribose toxicity, pharmacokinetics, and DNA incorporation in athymic mouse tissues and a human colon cancer xenograft (HCT-116). Cancer Res 1994; 54:2695-2700.
60. Kinsella TJ, Kunugi KA, Vielhuber K et al. Preclinical evaluation of 5-iodo-2-pyrimidinone-2′-deoxyribose (IPdR) as a prodrug for iododeoxyuridine (IUdR)-radiosensitization in mouse and human tissues. Proc Am Assoc Cancer Res 1996; 37:612.
61. Bruso CE, Shewach DS, Lawrence TS. Fluorodeoxyuridine-induced radiosensitization and inhibition of DNA double strand break repair in human colon cancer cells. Int J Radiat Oncol Biol Phys 1990; 19:1411-1417.
62. Heimburger DK, Shewach DS, Lawrence TS. The effect of fluorodeoxyuridine on sublethal damage repair in human colon cancer cells. Int J Radiat Oncol Biol Phys 1991; 21:983-987.
63. Lawrence TS, Maybaum J. Fluoropyrimidines as radiation sensitizers. Sem Radiat Oncol 1993; 3:20-28.
64. Heidelberger C, Griesbach L, Montag BJ et al. Studies on fluorinated pyrimidines II. Effects on transplanted tumors. Cancer Res 958; 18:305-309.
65. Thomas PR, Lindblad AS. Adjuvant postoperative radiotherapy and chemotherapy in rectal carcinoma: a review of the Gastrointestinal Tumor Study Group experience. Radiother Oncol 1988; 13:245-252.
66. Gastrointestinal Tumor Study Group: Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Cancer 1987; 59:2006-2010.
67. Gastrointestinal Tumor Study Group. Radiation therapy and fluorouracil with or without semustine for the treatment of patients with surgical adjuvant adenocarcinoma of the rectum. J Clin Oncol 1992; 10:549-557.
68. Krook JE, Moertel CG, Gunderson LL et al. Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Engl J Med 1991; 324:709-715.
69. O'Connell MJ, Martenson JA, Wieand HS et al. Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med 1994; 33:502-507.
70. Herskovic A, Martz K, al-Sarraf M et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med 1992; 24:1593-1598.
71. Anonymous. NIH consensus conference. Adjuvant therapy for patients with colon and rectal cancer. JAMA 1990; 264:1444-1450.
72. Byfield JE, Calabro-Jones P, Klisak LL, Kulhanian F. Pharmacologic requirements for obtaining sensitization of human tumor cells in vitro to combined 5-fluorouracil or ftorafur and x rays. Int J Radiat Oncol Biol Phys 1982; 8:1923-1933.
73. Byfield JE. Useful interactions between 5-fluorouracil and radiation in man: 5-fluorouracil as a radiosensitizer. In: Hill BT, Bellamy AS, eds. Antitumor Drug-Radiation Interactions. Boca Raton, Fla: CRC Press Inc., 1990:87-105.
74. Weinberg MJ, Lapointe TA, Rauth AM. Growth delay in a murine squamous cell tumor after local radiation and concurrent infusional 5-fluorouracil treatment. Int J Radiat Oncol Biol Phys 1986; 12:1449-1452.
75. Weinberg MJ, Rauth AM. 5-Fluorouracil infusion and fractionated dose of radiation: studies with a murine squamous cell carcinoma. Im J Radiat Oncol Biol Phys 1987; 13:1691-1699.
76. Lawrence TS, Davis MA, Maybaum J. Dependence of 5-fluorouracil-mediated radiosensitization on DNA-directed effects. Int J Radiat Oncol Biol Phys 1994; 29:59-523.
77. Davis MA, Tang HY, Maybaum J, Lawrence TS. Dependence of fluorodeoxyuridine-mediated radiosensitization on S phase progression. Int J Radiat Biol 1995; 67:509-512.
78. McGinn CJ, Miller EM, Lindstrom MJ et al. The role of cell cycle redistribution in radiosensitization: implications regarding the mechanism of fluorodeoxyuridine radiosensitization. Int J Radiat Oncol Biol Phys 1994; 30:851-859.
79. Keyomarsi K, Samet J, Molinar G, Pardee AB. The thymidylate synthase inhibitor, ICI D1694, overcomes translational detainment of the enzyme. J Biol Chem 1993; 268:15142-15149.
80. Smith IE, Speilmann M, Bonneterre J et al. Tomudex (ZD 1694), a new thymidylate synthase inhibitor with antitumor activity in breast cancer. Ann Oncol 1994; 5:242-249.
81. Cunningham D, Zalcberg JR, Rath U et al. Tomudex (ZD 1694): Results of a randomized trial in advanced colorectal cancer demonstrate efficacy and reduced mucositis and leucopenia. Eur J Cancer 1995; 31:1945-1954.
82. Glennon MC, Johnston PG, Kinsella TJ. ZD1694 (Tomudex) modulation of 5-iododeoxyuridine incorporation into DNA. Proc Am Assoc Cancer Res 1995; 36:612.
83. Yarbro JW. Mechanism of action of hydroxyurea. Semin Oncol 1992;19(S9):1-10.
84. Donehower RC. An overview of the clinical experience with hydroxyurea. Semin Oncol 1992; 19 (S9):11-19.
85. Vokes EE, Beckett M, Karrison T, Weichselbaum RR. The interaction of 5-fluorouracil, hydroxyurea, and radiation in two human head and neck cancer cell lines. Oncology 1992; 49:454-460.